Comirnaty (Pfizer) was registered by the TGA on 28 January 2022 for use as a booster in the 16-17 year age group. ATAGI now extends the recommendation of a booster dose to include all individuals aged 16-17 years. This clinical recommendation aims to maximise protection for this age group who are at a critical point in their secondary education and early working lives. People in this age group are also very mobile and may engage in increased social mixing. Comirnaty (Pfizer) is the only vaccine registered for use as a booster for people aged 16-17 years at present.
Evidence demonstrates that waning of protection against the Omicron variant